FDA Announces Public Meeting on Listeria monocytogenes Prevention

FDA Launches New Public Engagement Initiative on Listeria Prevention

The U.S. Food and Drug Administration (FDA) has announced a public meeting focused on the prevention of Listeria monocytogenes, scheduled for August 18-19, 2026. The meeting represents the first in a planned series of public engagements, including future workshops and webinars, aimed at advancing strategies to reduce the risks associated with L. monocytogenes throughout the food supply chain.

According to FDA, these discussions will help inform ongoing agency efforts by incorporating stakeholder perspectives while also considering the latest scientific advancements and emerging developments in Listeria prevention.

Why Listeria Remains a Priority

Listeria monocytogenes continues to be one of the most significant foodborne pathogens from a public health perspective. While outbreaks are relatively infrequent compared to some other foodborne illnesses, listeriosis can result in severe illness, hospitalization, and death, particularly among vulnerable populations.

Ready-to-eat foods remain a particular area of concern because contamination can occur after processing and products may be consumed without a kill step before consumption.

Key Discussion Topics

FDA has identified four primary areas of focus for the meeting:

1. Reducing L. monocytogenes During Manufacturing and Processing

Discussion will include approaches to preventing contamination within food production environments, including sanitation, environmental monitoring, hygienic design, and process controls.

2. Reducing Risks in Retail Settings

Stakeholders will examine strategies to minimize contamination and cross-contamination risks in retail environments handling ready-to-eat foods.

3. Consumer Storage and Use Practices

The meeting will explore ways to reduce risks associated with consumer handling, refrigeration, and storage practices.

4. Improving Awareness Among Vulnerable Populations

FDA plans to discuss methods for increasing awareness among groups at higher risk for severe listeriosis, including older adults, pregnant individuals, and those with weakened immune systems.

What This Means for Industry

The public meeting signals FDA’s continued emphasis on proactive Listeria control and prevention. Food manufacturers producing ready-to-eat products should continue to evaluate:

• Environmental monitoring programs
• Sanitation and cleaning procedures
• Hygienic zoning practices
• Equipment and facility design
• Supplier controls
• Corrective action and root cause investigation procedures

The discussions may also provide insight into future FDA expectations, guidance development, and educational initiatives related to Listeria prevention.

Meeting Information

The public meeting will be held:

August 18-19, 2026
Harvey W. Wiley Federal Building
College Park, Maryland

Attendance is available both in person and virtually. Registration is required, but there is no fee to participate.

EAS Perspective

FDA’s decision to launch a broader public engagement initiative focused on Listeria monocytogenes reflects the agency’s ongoing commitment to reducing foodborne illness through prevention. Companies producing ready-to-eat foods may benefit from monitoring these discussions closely, as they could provide valuable insight into emerging best practices, scientific developments, and future regulatory expectations related to environmental monitoring and pathogen control programs.